BNTX supply chain intelligence for BioNTech SE: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
BioNTech SE (BNTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from BNTX graph: usiness and financial condition, including, among other things: • delays to the development timelines for our product… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | usiness and financial condition, including, among other things: • delays to the development timelines for our product candidates; • interruption of supply resulting from modifications to or discontin… |
| AUTL | Autolus Therapeutics plc | 72% | Reciprocal relationship from AUTL graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from AUTL graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from AUTL g… |
| BCAX | Bicara Therapeutics Inc. | 72% | Reciprocal relationship from BCAX graph: inancial institutions where we maintain our cash, cash equivalents and marketable securities, there can be no assurance that we would be able to access uninsu… |
| CBIO | Crescent Biopharma, Inc. | 72% | Reciprocal relationship from CBIO graph: ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because of this lack of experience, we cannot be … |
| EVAX | Evaxion A/S | 72% | Reciprocal relationship from EVAX graph: drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pres… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from MGNX graph: n exclusive option to license worldwide rights to the research program, upon… |
| MRVI | Maravai LifeSciences Holdings, Inc. | 72% | Reciprocal relationship from MRVI graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from MRVI graph: able were $ million during the year ended December 31, 2024 . Write-offs of … |
| MTNB | Matinas BioPharma Holdings, Inc. | 72% | Reciprocal relationship from MTNB graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from MTNB graph: . The lease impairment charges were included in the impairment charges of ot… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from BNTX graph: If and when we receive full marketing authorization for our COVID-19 vaccine, we will market our products through pe… |
| NVSEF | Novartis AG | 72% | If and when we receive full marketing authorization for our COVID-19 vaccine, we will market our products through personal interactions with physicians and allied health care professionals. Our gover… |
| ROIV | Roivant Sciences Ltd. | 72% | Reciprocal relationship from ROIV graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from ROIV g… |
| SMMT | Summit Therapeutics Inc. | 72% | Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”).… |
| SNYNF | Sanofi | 72% | . Other collaboration programs have been progressed during the year ended December 31, 2020 and revenues of €52.1 million have been derived from deferred upfront payments measured based on the costs … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from BNTX graph: . Other collaboration programs have been progressed during the year ended December 31, 2020 and revenues of €52.1 mi… |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 72% | Reciprocal relationship from TNXP graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from TNXP graph: arket strategy. Our commercialization strategy for TONMYA is centered on a c… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AUTL | Autolus Therapeutics plc | 80% | Reciprocal relationship from AUTL graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from AUTL graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from AUTL g… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from BNTX graph: usiness and financial condition, including, among other things: • delays to the development timelines for our product… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | usiness and financial condition, including, among other things: • delays to the development timelines for our product candidates; • interruption of supply resulting from modifications to or discontin… |
| AUTL | Autolus Therapeutics plc | 72% | 1,254.0 9,739.6 92.7 11.9 41.1 9,739.6 Cash and cash equivalents Cash at banks and on hand Yes AC 450.0 — 450.0 — — — 450.0 Money market funds Yes FVTPL 6,947.5 — 6,947.5 6,947.5 — — 6,947.5 Deposits… |
| EVAX | Evaxion A/S | 72% | Reciprocal relationship from EVAX graph: g Phase 2b trial, we are required to pay to SSI a percentage of any sublicensing income in the mid double-digit range. Prior to any out-licensing or commercia… |
| GNMSF | Genmab A/S | 72% | 5,396 2,349 Other operating expenses (739) (720) (288) Operating loss €(181,518) €(53,854) €(61,277) Finance income 4,122 8,046 2,133 Finance expenses (326) (48) (26,007) Interest expense related to … |
| GNMSF | Genmab A/S | 72% | Reciprocal relationship from GNMSF graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from GNMSF graph: Reciprocal relationship from BNTX graph: 5,396 2,349 Other operating expen… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from LLY grap… |
| LLY | Eli Lilly and Company | 72% | 5,396 2,349 Other operating expenses (739) (720) (288) Operating loss €(181,518) €(53,854) €(61,277) Finance income 4,122 8,046 2,133 Finance expenses (326) (48) (26,007) Interest expense related to … |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from MGNX graph: t and future product candidates. Most of the principal materials we use in o… |
| MTNB | Matinas BioPharma Holdings, Inc. | 72% | Reciprocal relationship from MTNB graph: contractors associated with Chemistry and Manufacturing Controls (CMC), pre-clinical and clinical activities and regulatory operations; ● expenses incurred un… |
| NVSEF | Novartis AG | 72% | If and when we receive full marketing authorization for our COVID-19 vaccine, we will market our products through personal interactions with physicians and allied health care professionals. Our gover… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BNTX graph: If and when we receive full marke… |
| ROIV | Roivant Sciences Ltd. | 72% | Reciprocal relationship from ROIV graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from ROIV graph: y need to obtain licenses from third parties to advance our research or allo… |
| SMMT | Summit Therapeutics Inc. | 72% | Reciprocal relationship from SMMT graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin… |
| SNYNF | Sanofi | 72% | s unit decreased by €2.6 million, or 63%, to €1.5 million in the year ended December 31, 2019 from €4.1 million in the year ended December 31, 2018. This decrease was primarily attributable to a decr… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from SNYN… |
| BMY | Bristol-Myers Squibb Company | 62% | Reciprocal relationship from BMY graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from BMY graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from BMY grap… |
| GSK | GSK plc | 62% | Reciprocal relationship from GSK graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from GSK graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from GSK grap… |
| INSTADEEP-LTD | INSTADEEP-LTD | 62% | to identify, recruit and retain key personnel; – our and our collaborators’ ability to protect and enforce our intellectual property protection for our proprietary and collaborative product candidate… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| BNTX-DEBT | Debt stack $353.0M | 90% | Market cache reports total debt of $353.0M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| BNTX-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME | T. Rowe Price Investment Management, Inc. | 90% | 13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 274 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['customer'] |
| INCY | Incyte Corporation | 100.00 | 2 | |
| CAH | Cardinal Health, Inc. | 100.00 | 2 | |
| EVAX | Evaxion A/S | 100.00 | 1 | ['customer', 'supplier'] |
| GSK | GSK plc | 100.00 | 2 | ['customer'] |
| INBX | Inhibrx Biosciences, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| ECO | Okeanis Eco Tankers Corp. | 100.00 | 2 | |
| CMPX | Compass Therapeutics, Inc. | 100.00 | 2 | |
| CLLS | Cellectis S.A. | 100.00 | 2 | |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 100.00 | 2 | |
| GILD | Gilead Sciences, Inc. | 100.00 | 2 | |
| GNMSF | Genmab A/S | 100.00 | 2 | ['customer'] |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 1 | ['supplier'] |
| AUTL | Autolus Therapeutics plc | 100.00 | 1 | ['customer', 'supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BCAX | Bicara Therapeutics Inc. | 100.00 | 1 | ['supplier'] |
| ARTV | Artiva Biotherapeutics, Inc. | 100.00 | 2 | |
| MGNX | MacroGenics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |